This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acquisition Of Conceptus, Inc. By Bayer HealthCare LLC May Not Be In The Best Interests Of Conceptus Shareholders

SAN DIEGO and MOUNTAIN VIEW, Calif., April 29, 2013 /PRNewswire/ --  Shareholder rights attorneys at Robbins Arroyo LLP are investigating the acquisition of Conceptus, Inc. (NASDAQ: CPTS) by Bayer HealthCare LLC.  On April 29, 2013, Bayer announced the signing of a merger agreement with Conceptus whereby Bayer will launch a public tender offer to acquire all the shares of Conceptus for $31.00 per share.  The transaction is expected to close by mid-year 2013.  Conceptus is best known for developing the Essure procedure, the only surgery-free permanent birth control method.


The Board of Directors' Actions May Prevent Conceptus Shareholders from Receiving Maximum Value for Their Stock

Robbins Arroyo LLP's investigation focuses on whether the board of directors at Conceptus is undertaking a fair process to obtain maximum value and adequately compensate its shareholders in the merger.  On February 5, 2013, Conceptus released its fourth quarter 2012 and full year 2012 earnings reflecting strong sales and revenues.  Notably, the fourth quarter 2012 experienced substantial growth in: (i) total revenues, which were up 21.5% to $40.7 million, (ii) U.S. sales, up 19.3% to $32.2 million and; (iii) international sales, which experienced a growth of 30.8% to $8.5 million. Further, the full year 2012 experienced similar success, with: (i) total revenue reaching $140.7 million, a 10.8% increase, (ii) U.S. sales growing 13.1% to $109.1 million, and; (iii) international sales up 3.6% percent to $31.6 million. Moreover, Conceptus expects its success to continue, estimating 2013 sales to be in the range of $155 million to $159 million, a growth of 10% to 13% over 2012 sales.

Given these facts, the firm is examining the board of directors' decision to sell Conceptus now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects.   

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.13 -1.10%
FB $117.76 -0.25%
GOOG $703.36 1.10%
TSLA $211.24 -5.10%
YHOO $37.04 2.90%


Chart of I:DJI
DOW 17,641.02 -19.69 -0.11%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs